Last reviewed · How we verify

Ropivacaine + dexamethasone

Sahiwal medical college sahiwal · FDA-approved active Small molecule

Ropivacaine blocks sodium channels to provide local anesthesia, while dexamethasone reduces inflammation and prolongs the duration of anesthetic effect.

Ropivacaine blocks sodium channels to provide local anesthesia, while dexamethasone reduces inflammation and prolongs the duration of anesthetic effect. Used for Local and regional anesthesia for surgical procedures, Peripheral nerve blocks with prolonged analgesia.

At a glance

Generic nameRopivacaine + dexamethasone
Also known asSupraclavicular Brachial Plexus Block with Ropivacaine and Dexamethasone
SponsorSahiwal medical college sahiwal
Drug classLocal anesthetic with corticosteroid adjuvant
TargetVoltage-gated sodium channels; glucocorticoid receptor
ModalitySmall molecule
Therapeutic areaAnesthesia / Pain Management
PhaseFDA-approved

Mechanism of action

Ropivacaine is a long-acting amide local anesthetic that reversibly inhibits sodium influx in nerve fibers, preventing depolarization and action potential propagation. Dexamethasone, a corticosteroid, is added to reduce perioperative inflammation and extend the duration of anesthesia by decreasing vascular uptake of the local anesthetic and modulating inflammatory mediators at the injection site.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: